Program
Artesunate
Also written as “Artesunate + Amodiaquine”, “Artesunate ointment” and “Artesunate vaginal insert”.
Its studies are mostly in Malaria · Papillomavirus Infections · Malaria, Falciparum · Cytomegalovirus Infections · Vulvar Diseases, led by 7 companies.
Drug pageArtesunate: every studyMany companies study it; this page follows only the 17 they lead. All 115 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 60 open or running | phase 4since Mar 8, 2007 | Apr 18, 2006 | none ahead |
| Frantz Viral Therapeutics | 44 open or running | phase 2since Sep 19, 2019 | Sep 19, 2019 | Dec 2026phase 2 · NCT06075264 |
| Metanoic Healthits history only | 22 open or running | phase 2since Jul 7, 2025 | Jul 7, 2025 | Jun 30, 2027phase 2 · NCT07095478 |
| Shin Poong Pharmaceuticalits history only | 20 open or running | phase 2since Sep 13, 2018 | Sep 13, 2018 | none ahead |
| Amivasits history only | 11 open or running | phase 2since Feb 25, 2025 | Feb 25, 2025 | May 31, 2028phase 2 · NCT06853184 |
| Pfizerits history only | 10 open or running | phase 1since May 4, 2009 | May 4, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 4since Sep 10, 2009 | Sep 10, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Frantz Viral Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2019First study: phase 2 study in Papillomavirus InfectionsFirst studyNCT04098744 · 78 planned · United States
- Sep 22, 2022Phase 2 study in Papillomavirus InfectionsNCT05555862 · 17 enrolled · United States
- Oct 4, 2023Phase 2 study in Vulvar DiseasesNCT06075264 · 27 planned · United States
- Jan 3, 2024Phase 2 study in Anal High-grade Squamous Intraepithelial LesionNCT06206564 · 48 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Vulvar DiseasesNCT06075264
- Dec 28, 2026Primary completion: phase 2 study in Papillomavirus InfectionsNCT05555862
- Dec 31, 2026Primary completion: phase 2 study in Anal High-grade Squamous Intraepithelial LesionNCT06206564
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 Frantz Viral Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06206564Anal High-grade Squamous Intraepithelial Lesion · United States | 2 | Recruiting | Dec 31, 2026 | 48 |
| NCT06075264Vulvar Diseases · United States | 2 | Recruiting | Dec 2026 | 27 |
| NCT05555862Papillomavirus Infections · United States | 2 | Active, not recruiting | Dec 28, 2026 | 17 |
| NCT04098744Papillomavirus Infections · United States | 2 | Recruiting | Jul 31, 2026 | 78 |
How it is read
Names in the registry
- “Artesunate”, 6 entries
- “Artesunate + Amodiaquine”, 3 entries
- “Artesunate ointment”, 2 entries
- “Artesunate vaginal insert”, 1 entry
- “Artesunate-amodiaquine”, 1 entry
Conditions, from the studies’ own filings
- Malaria, 7 studies
- Papillomavirus Infections, 3 studies
- Malaria, Falciparum, 2 studies
- Cytomegalovirus Infections, 1 study
- Vulvar Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.